The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Impact of prior lines of therapy before ASCT and CAR-T on aggressive NHL
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, talks on the impact of prior lines of therapy before autologous stem cell transplant (ASCT) and CAR-T infusion on the outcomes of aggressive non-Hodgkin’s lymphoma (NHL). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultant: Kite/Gilead, Celgene/BMS, JUNO/BMS, BlueBird Bio, Janssen, Legend BioTech, Gamida Cells, Novartis, Iovance, Takeda, Fosun Kite
Grant/Research Support: Kite/Gilead, Celgene, BlueBird Bio, Janssen, Legend Biotech, Merck, Takeda, Boston Scientific
Data safety monitoring board: Sorrento
All funds paid to Mayo Clinic, no personal compensation.
